onc Videos

Videos

Sarah Smith, Virginia Cancer Specialists

Videos

Post-Progression and Safety Outcomes With First-Line Amivantamab Plus Lazertinib vs Osimertinib for Advanced NSCLC: Best Management Practices

05/24/2024

Sarah Smith, BD, CNMT, discusses findings from the phase 3 MARIPOSA study exploring post-progression and safety outcomes with first-line amivantamab plus lazertinib vs osimertinib for advanced NSCLC and offers guidance for best management...

Sarah Smith, BD, CNMT, discusses...

05/24/2024

Oncology

Videos

Pediatric Ganglioglioma With a BRAF KIAA1549 Fusion

05/24/2024

Mohamed S. Abdelbaki, MD

Mohamed S. Abdelbaki, MD, discusses the course of treatment he would take for a patient with pediatric ganglioglioma with a BRAF KIAA1549 fusion.

Mohamed S. Abdelbaki, MD,...

05/24/2024

Oncology

Conference Coverage

Transarterial Chemoembolization Plus Immunotherapy for Patients With Hepatocellular Carcinoma

05/23/2024

Adam Talenfeld, MD

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Adam Talenfeld, MD, argued in favor of using transarterial chemoembolization alongside immune checkpoint blockade to treat patients with hepatocellular...

At Great Debates and Updates in...

05/23/2024

Oncology

Conference Coverage

Transarterial Chemoembolization Plus Immune Checkpoint Blockade for Patients With Hepatocellular Carcinoma

05/22/2024

James Harding, MD

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, James Harding, MD, discussed results from the EMERALD-1 study which demonstrated that transarterial chemoembolization plus immune checkpoint blockade...

At Great Debates and Updates in...

05/22/2024

Oncology

Conference Coverage

Consideration of Long Course Radiation for Patients With Rectal Cancer

05/21/2024

Jennifer Wo, MD

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Jennifer Wo, MD, discussed use of long course neoadjuvant radiation therapy for the treatment of patients with rectal cancer.

At Great Debates and Updates in...

05/21/2024

Oncology

Videos

Pediatric Pilocytic Astrocytoma With a KIAA1549:BRAF Fusion

05/20/2024

Shubin Shahab, MD, PhD

Shubin Shahab, MD, PhD, discusses how to treat a patient with pediatric pilocytic astrocytoma with a KIAA1549:BRAF fusion.

Shubin Shahab, MD, PhD,...

05/20/2024

Oncology

Conference Coverage

PD-1 Inhibitors for First-Line Treatment of Patients With Gastroesophageal Cancers

05/18/2024

Ryan Moy, MD

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Ryan Moy, MD, PhD, discussed first-line use of PD-1 inhibitors for the treatment of patients with gastroesophageal cancers.

At Great Debates and Updates in...

05/18/2024

Oncology

Conference Coverage

Claudin-18.2 Inhibitors for First-Line Treatment of Patients With Gastroesophageal Cancer

05/18/2024

Samuel Cytryn, MD

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Samuel Cytryn, MD, discussed first-line use of claudin-18.2 inhibitors for patients with gastroesophageal cancers.

At Great Debates and Updates in...

05/18/2024

Oncology

Conference Coverage

Should Docetaxel Plus Ramucirumab Be the Standard Second-Line Option for Patients With Non-Small Cell Lung Cancer?

05/15/2024

Edward Garon, MD

At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Edward Garon, MD, MS, argued that docetaxel plus ramucirumab should be the standard second-line option for patients with NSCLC.

At the Great Debates and Updates...

05/15/2024

Oncology

Conference Coverage

The Case Against Antibody Drug Conjugates for Patients With Lung Cancers

05/15/2024

Corey Langer, MD

At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Corey Langer, MD, argued that antibody drug conjugates are not ready to replace TROP-2 inhibitors as the standard of care for patients with lung cancers.

At the Great Debates and Updates...

05/15/2024

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology